Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Pediatric Vouchers Can Have Heavy Adult Involvement, FDA Says

Nov 24 2014

• By Derrick Gingery

Related Content

FDA Orphan Approval Flexibility Remains Steady As Pressure Increases

Oct 27 2014

Review Cost For Sanofi/Regeneron’s PCSK9 Inhibitor Remains Uncertain

Sep 16 2014

How Much Is A Priority Review Worth? $67.5 Million, Sanofi/Regeneron Say

Aug 11 2014

Priority Review Weirdness: Tropical Voucher Sells For More; Owner Says It’s Worth Less

Nov 24 2014

Ebola Drugs Take Center Stage In Review Voucher Bill, But Real Value May Be Harmonization

Nov 24 2014

Related Companies

BioMarin Pharmaceutical Inc.

Sanofi

Regeneron Pharmaceuticals, Inc.

Knight Therapeutics, Inc.

Gilead Sciences, Inc.

Additional Topics

United States Post Market Regulation & Studies Regulation BioPharmaceutical

More from United States

More from North America

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window